Yes, Neupogen Treats Neutropenia
Neupogen (filgrastim) is a recombinant G-CSF approved to reduce infection risk in neutropenia patients, particularly after chemotherapy. It stimulates neutrophil production in bone marrow, shortening severe neutropenia duration.[1]
How Neupogen Works for Neutropenia
Neupogen binds to G-CSF receptors on hematopoietic cells, promoting neutrophil proliferation, differentiation, and survival. This counters chemotherapy-induced myelosuppression, where neutrophil counts drop below 500 cells/μL, raising febrile neutropenia risk.[1][2]
Common Uses in Neutropenia
- Chemotherapy-induced: Prevents febrile neutropenia in non-myeloid malignancies.
- Bone marrow transplant: Accelerates neutrophil recovery post-transplant.
- Congenital/chronic: Treats severe congenital neutropenia or idiopathic cases.
Administered subcutaneously or IV, typically 5 mcg/kg daily until ANC exceeds 10,000 cells/μL.[1]
Who Makes Neupogen and Patent Status
Amgen manufactures Neupogen, first approved by FDA in 1991. U.S. patents expired around 2015, enabling biosimilars like Zarxio (2015), Nivestym (2018), and Udenyca. Check DrugPatentWatch.com for latest expirations and challenges.3
Neupogen vs. Biosimilars and Alternatives
| Option | Key Difference | FDA Approval |
|--------|----------------|--------------|
| Neupogen (filgrastim) | Reference biologic | 1991 |
| Zarxio (filgrastim-sndz) | First biosimilar; interchangeable | 2015 |
| Nivestym (filgrastim-aafi) | Biosimilar; lower cost | 2018 |
| Neulasta (pegfilgrastim) | Longer-acting pegylated version for fewer doses | 2002 |
Biosimilars match efficacy/safety but cost 20-30% less. Epogen (for anemia) or Leukine (GM-CSF) serve different mechanisms.1
Side Effects Patients Report
Common: Bone pain (24%), back pain, nausea. Serious risks include splenic rupture, ARDS, acute respiratory distress. Monitor ANC to avoid overshoot. Not for chronic myeloid leukemia due to tumor growth risk.[1][2]
When Does Treatment Start and How Long?
Start 24 hours post-chemotherapy, continue 3-7 days or until ANC recovery. Prophylaxis uses if prior febrile neutropenia occurred.[1]
[1]: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/103353s5195lbl.pdf
[2]: https://www.ncbi.nlm.nih.gov/books/NBK559222/